Now, Janus Henderson Slashes PharmEasy’s Valuation By 50%

Now, Janus Henderson Slashes PharmEasy’s Valuation By 50%

SUMMARY

As per the filings of the global asset management company, it has slashed PharmEasy’s valuation by 50% to $2.8 Bn

The development comes days after it was reported that Neuberger Berman trimmed the valuation of the epharmacy unicorn to $4.4 Bn

Amid the funding winter and falling valuations of tech companies globally, multiple startups like Ola, Swiggy, Pine Labs, BYJU’S, and OYO have seen their investors trimming their valuations

Amid the global economic slowdown and valuation markdown season, PharmEasy has received another valuation cut. The epharmacy unicorn’s investor Janus Henderson has reportedly slashed its valuation to about $2.8 Bn.

The global asset management company’s filings with the US Securities and Exchange Commission (SEC) showed that it has cut the valuation of its holding in PharmEasy by 50%, ET reported. 

Janus Henderson picked a stake in PharmEasy in September 2021.

The development comes days after it was reported that New York-based investment firm Neuberger Berman trimmed the valuation of the epharmacy startup to $4.4 Bn from $5.6 Bn in October 2021. 

Amid the ongoing funding winter and falling valuations of tech companies globally, multiple Indian startups like Ola, Swiggy, Pine Labs, BYJU’S, and OYO have seen their investors trimming their valuations.

Along with PharmEasy, Neuberger Berman also cut the valuation of Pine Labs to $3.1 Bn from $5 Bn in July 2021. Meanwhile, Vanguard Group recently reduced the valuation of ride-hailing startup Ola by 35% to $4.8 Bn.

Earlier this month, it was reported that Invesco cut the valuation of Swiggy to $5.5 Bn as of October 2022 from $10.7 Bn in January 2021.

Last month, BlackRock also trimmed the valuation of edtech unicorn BYJU’S by almost 50% to $11.5 Bn.

Last year, PharmEasy deferred its plans to list on the Indian stock exchanges citing valuation mismatch and market volatility. However, it was not the only startup to do so as multiple Indian new-age tech companies like ixigo, Pine Labs, and Capillary Technologies postponed or cancelled their planned initial public offerings (IPOs) amidst a bloodbath on the exchanges.

PharmEasy filed its draft red herring prospectus (DRHP) with SEBI in November 2021 to raise INR 6,250 Cr. After deferring its IPO, the startup raised INR 750 Cr in October 2022. While Prosus picked up convertibles worth INR 100 Cr, Temasek subscribed to convertibles of nearly INR 90 Cr.

PharmEasy also laid off several employees last year. While Inc42 reported about 40 layoffs at the startup in June last year, more employees were laid off in the latter half of the year.

You have reached your limit of free stories
Become An Inc42 Plus Member

Become a Startup Insider in 2024 with Inc42 Plus. Join our exclusive community of 10,000+ founders, investors & operators and stay ahead in India’s startup & business economy.

2 YEAR PLAN
₹19999
₹7999
₹333/Month
Unlock 60% OFF
Cancel Anytime
1 YEAR PLAN
₹9999
₹4999
₹416/Month
Unlock 50% OFF
Cancel Anytime
Already A Member?
Discover Startups & Business Models

Unleash your potential by exploring unlimited articles, trackers, and playbooks. Identify the hottest startup deals, supercharge your innovation projects, and stay updated with expert curation.

Now, Janus Henderson Slashes PharmEasy’s Valuation By 50%-Inc42 Media
How-To’s on Starting & Scaling Up

Empower yourself with comprehensive playbooks, expert analysis, and invaluable insights. Learn to validate ideas, acquire customers, secure funding, and navigate the journey to startup success.

Now, Janus Henderson Slashes PharmEasy’s Valuation By 50%-Inc42 Media
Identify Trends & New Markets

Access 75+ in-depth reports on frontier industries. Gain exclusive market intelligence, understand market landscapes, and decode emerging trends to make informed decisions.

Now, Janus Henderson Slashes PharmEasy’s Valuation By 50%-Inc42 Media
Track & Decode the Investment Landscape

Stay ahead with startup and funding trackers. Analyse investment strategies, profile successful investors, and keep track of upcoming funds, accelerators, and more.

Now, Janus Henderson Slashes PharmEasy’s Valuation By 50%-Inc42 Media
Now, Janus Henderson Slashes PharmEasy’s Valuation By 50%-Inc42 Media
You’re in Good company